TRUTAKNA, an FDA-approved IgAN treatment, met all primary endpoints in the ORIGIN 3 trial with favorable safety results.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results